Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The results from the SUSTAIN 6 trial indicated that patients treated with semaglutide experienced a significantly higher incidence of DR compared to those receiving placebo (86)
Why Choose MedLeanRx
Methods Study design The SEMPA trial (Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in Patients with Type 2 Diabetes A Randomized Trial) was a 32 week investigator-initiated, randomised, partly placebo-controlled, partly open-label trial, designed to assess the separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and arterial stiffness as two co-primary outcomes
Some states cover GLP-1 medications for diabetes but not weight loss, while others have implemented strict utilization management programs requiring extensive documentation before approval
US$ 29.19
US$ 26.32
US$ 21.97
US$ 23.52
